Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study

Maniscalco, Giorgia Teresa; Scavone, Cristina; Moreggia, Ornella; Cesare, Daniele Di Giulio; Aiezza, Maria Luisa; Guglielmi, Gaspare; Longo, Giuseppe; Maiolo, M; Raiola, Eliana; Russo, Giuseppe; Capuano, Annalisa

doi:10.1080/14740338.2022.2044787

Cited by 6 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the limitations of our study is the sample size (260), which, despite being larger than that used by other authors (e.g., 101 [ 20 ] or 194 [ 9 , 31 ]), may have obtained results that were not very precise and had wide confidence intervals. Nevertheless, the mentioned sample size exceeded 236 persons, which was the minimum number of patients to be included, considering a precision of 5%, alpha error of 5%, and expected vaccination coverage of 19.0% [ 8 ].…”

Section: Discussionmentioning

confidence: 89%

Influenza Vaccination Coverage among Multiple Sclerosis Patients: Evolution over Time and Associated Factors

Hernández-García

Garcés-Redondo²,

Rodríguez-Montolio³

et al. 2022

Vaccines

View full text Add to dashboard Cite

Our objective was to determine the influenza vaccination rate in a Spanish cohort of multiple sclerosis (MS) patients. A retrospective cohort study was carried out. Patients who attended the MS unit of the Lozano Blesa Hospital of Zaragoza between January 2015 and 2020 were included. The variables were obtained by reviewing the specialized and primary care records. Associations between receiving the vaccine in each flu season and the other variables were analyzed using bivariate analysis and multiple logistic regression models. A total of 260 patients were studied, with a median age of 31 years at the time of diagnosis. A total of 62.3% (162/260) were women. Vaccination coverage ranged from 20.4% in the 2015–2016 and 2016–2017 seasons to 41.5% in the 2019–2020 season (p = 0.000). Having been vaccinated in the previous season (ORa: 16.47–390.22; p = 0.000) and receiving a vaccination recommendation from the hospital vaccination unit (ORa: 2.44–3.96; p < 0.009) were associated with being vaccinated. The coverage is in an intermediate position compared to other countries. It is necessary to improve the referral system of these patients to the hospital vaccination unit because the information obtained by this service contributed to higher vaccination rates.

show abstract

Section: Discussionmentioning

confidence: 89%

Influenza Vaccination Coverage among Multiple Sclerosis Patients: Evolution over Time and Associated Factors

Hernández-García

Garcés-Redondo²,

Rodríguez-Montolio³

et al. 2022

Vaccines

View full text Add to dashboard Cite

show abstract

“…This is, to our knowledge, the first study to evaluate the 2020–2021 influenza vaccination coverage in people with MS in Spain. The rate obtained is moderate with respect to those documented internationally [ 12 , 13 , 15 , 16 , 17 , 23 , 24 ], where, in the 2020–2021 season, coverages of 45.4% [ 16 ] to 63.8% [ 15 ] and 68.6% [ 24 ] were described in persons with MS in Latin America [ 16 ], Ireland [ 15 ] and Italy [ 24 ], respectively.…”

Section: Discussionmentioning

confidence: 56%

“…Among the limitations of this study is the sample size (302), which, although larger than the sample sizes in other studies [ 15 , 17 , 23 , 24 ] (from 101 [ 23 ] to 194 [ 17 ]), may have led to imprecise results. Nevertheless, the sample size is greater than 291, which is the minimum number to be studied considering a confidence level of 95%, a precision of 5%, a population of 1300 people [ 20 ] and an expected vaccination rate of 41.5% [ 14 ].…”

Section: Limitations and Strengthsmentioning

confidence: 87%

Influenza Vaccination among Multiple Sclerosis Patients during the COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

In the context of the COVID-19 pandemic, the co-circulation of influenza and SARS-CoV-2 viruses may have severe complications for vulnerable populations. For this reason, the World Health Organization pointed to the 2020–2021 anti-influenza campaign as being of special relevance. Our aim was to assess the 2020–2021 influenza vaccination coverage, and its associated factors, among patients in a Spanish multiple sclerosis (MS) unit. A cross–sectional study was conducted. People attending the MS unit of the Clinical Hospital of Zaragoza during 2020 were included. Variables were obtained by reviewing records. Associations with 2020–2021 influenza vaccination were analyzed using bivariate analysis and a multiple logistic regression model. A total of 302 patients were studied; 62.6% were women, whose mean age (standard deviation) was 47.3 (11.5) years. The 2020–2021 influenza vaccination coverage was 55.3% (59.8% in women and 47.8% in men). A total of 89.7% had at least one other indication for vaccination (e.g., immunosuppressive treatment in 225 patients). The variables associated with getting vaccinated were being female (adjusted odds ratio (95% confidence interval) (aOR (95%CI) = 2.12 (1.12–3.99)), having received the 2019–2020 influenza vaccine (aOR (95%CI) = 31.82 (14.71–68.86)) and being born in Spain (aOR (95%CI) = 12.91 (1.07–156.28)). Coverage is moderate compared to other countries. It is necessary to develop strategies to improve it, especially in men and those born outside Spain.

show abstract

“…Generally, doctors, followed by nurses and other health workers, represent the primary sources of spontaneous reports, especially in South Italy [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ]. Several initiatives have been implemented, and others are still necessary to implement a pharmacovigilance culture among all healthcare professionals and the general population [ 32 , 33 , 34 , 35 , 36 , 37 ]. The pressure to which healthcare personnel have been subjected during the COVID-19 emergency is well known.…”

Section: Discussionmentioning

confidence: 99%

Did the COVID-19 Pandemic Affect Contrast Media-Induced Adverse Drug Reaction’s Reporting? A Pharmacovigilance Study in Southern Italy

Rossi

Ruggiero

Sportiello

et al. 2022

JCM

View full text Add to dashboard Cite

Medical imaging is required for a complete clinical evaluation to identify lung involvement or pulmonary embolism during SARS-CoV-2 infection or pulmonary and cardiovascular sequelae. Contrast media (CM) have undoubtedly been useful in clinical practice due to their ability to improve medical imaging in COVID-19 patients. Considering their important use, especially in hospitalized COVID-19 patients, and that increased use of a medical tool could also be associated with its deeper knowledge, we chose to explore if new information emerged regarding CM safety profiles. We analyzed all Individual Case Safety Reports (ICSRs) validated by Campania Pharmacovigilance Regional Centre from 1 January 2018 to 31 December 2021 and reported a CM (ATC code V08) as a suspected drug. We compared CM-related reporting between 2 years before (period 1) and 2 years during (period 2) the COVID-19 pandemic. From our analysis, it emerged that, during the COVID-19 pandemic, CM-related ADR reporting decreased, but a significant increase in reporting of serious cases emerged. Serious ADRs were mainly related to iodinated CM (V08A ATC) compared to magnetic resonance imaging CM (V08C ATC). Cutaneous and respiratory disorders were the most frequently reported in both periods. No new or unknown ADRs were reported in the overall study period.

show abstract

Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study

Cited by 6 publications

References 20 publications

Influenza Vaccination Coverage among Multiple Sclerosis Patients: Evolution over Time and Associated Factors

Influenza Vaccination Coverage among Multiple Sclerosis Patients: Evolution over Time and Associated Factors

Influenza Vaccination among Multiple Sclerosis Patients during the COVID-19 Pandemic

Did the COVID-19 Pandemic Affect Contrast Media-Induced Adverse Drug Reaction’s Reporting? A Pharmacovigilance Study in Southern Italy

Contact Info

Product

Resources

About